RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
   Multiple Myeloma
   Non-Hodgkin's Lymphoma
  Bone Cancer
  Breast Cancer
  Cervical Cancer
  Gastric Cancer
  Liver Cancer
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Testicular Cancer
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Blood Channel

subscribe to Blood newsletter
Latest Research : Cancer : Blood

   EMAIL   |   PRINT
Lenalidomide Can Replace Blood Transfusions in Bone Marrow Disorder

May 18, 2005 - 1:45:00 AM
Lenalidomide is an anti-angiogenic agent that is similar to thalidomide.

[RxPG] A new study reports that the drug lenalidomide (RevLimid) can help some patients with myelodysplastic syndromes (MDS) avoid the need for blood transfusions, and even reduce or eliminate the genetic abnormality that characterizes the disease in this subset of patients.

Lenalidomide is an anti-angiogenic agent that is similar to thalidomide.

Myelodysplastic syndromes are a group of cancers in which the bone marrow does not make enough mature, functional blood cells. Patients commonly undergo blood transfusions every eight weeks to manage symptoms of anemia and fatigue caused by low red blood cell counts. MDS is the most common cancer of the blood in adults ­ more common than leukemia ­ affecting 40,000 to 50,000 Americans every year.

"Lenalidomide is a breakthrough for patients with MDS. This is the first effective therapy for this specific subtype of disease," said lead author Alan F. List, MD, Professor of Medicine at the H. Lee Moffitt Cancer Center in Tampa, Florida. Lenalidomide, which is taken orally, may work against MDS by inhibiting angiogenesis (the growth of blood vessels that tumor cancers need to grow), boosting the body's immune response against cancer, and enhancing red blood cell development.

Investigators examined the response to 10 mg of once-daily lenalidomide among 146 patients with MDS who relied on blood transfusions. All patients had a deletion of a region of genetic material on the long "q" arm of chromosome 5 ("del5q"). The trial was initiated in July 2003, and monitoring is ongoing. All patients who responded to the drug are continuing to take it as long as it remains effective.

After 24 weeks, 64% of patients responded to lenalidomide and did not need a transfusion. Seventy-six percent of those who responded experienced a reduction in the number of marrow cells that had the del5q abnormality, and 55% of responders had no evidence of the del5q abnormality. After a median follow-up of 9.3 months, 91% of responding patients continued to show a response to lenalidomide. The most common side effects were lowering of the white blood cell count (39% of patients) and platelet count (35%), which necessitated interruption of treatment or reduction of lenalidomide dose.

Publication: American Society of Clinical Oncology Annual Meeting
On the web: www.asco.org 

Advertise in this space for $10 per month. Contact us today.

Related Blood News

Subscribe to Blood Newsletter

Enter your email address:

 Additional information about the news article
Lead Author: Alan F. List, MD
H. Lee Moffitt Cancer Center Tampa, FL
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)